• Balancing the innovation and entrepreneurship of biotechs with the structure and organisation of big pharma
• Advantages of being big (financial strength and organisation resilience) versus the inhibitors (bureaucracy and inflexibility)
• Can you be big and small at once?
• Bridging the communication gap between pharma and biotech companies
• How can deal-making be improved if pharma learn a lesson or two from their biotech partners?

Business Development Focus: Mitigating The Risks Of Early Stage Deal-Funding In A Tough Climate

• Outlining the risks of funding early stage deals: how to prevent this
• Best practices and recommendations to ensure due diligence
• Ensuring the right deal with the right partner at the right time
• How can biotechs deliver maximum value to investors?

5 May 2010, Chicago

BIO Convention

Late Stage Trials, No Partner

Preparing for Commercialization while Simultaneously Talking to Partners

Whether because of a desire to get maximum value in partnering, macroeconomic conditions or other reasons, more biotechnology companies are finding themselves finishing late stage clinical trials, preparing their regulatory filings or awaiting approval without yet having secured a commercialization partner. Are there great opportunities for a flexible partner? How does such a situation affect valuation and partnering discussions? How does a biotech company begin labeling discussions, design marketing strategies and build a sales force without knowing whether these decisions will mesh with a future partner’s plans? What might a partner think? This panel will answer these questions and more.

Learning Objectives: Attendees will learn the following:

1. Concepts to consider in deciding when to partner or not.

2. Strategies for successfully negotiating and structuring late-stage partnering transactions.

3. Strategies for preparing to self-commercialize knowing that changes may be required by a future partner.

2 Feb 2010,

Geneva

BioSquare